Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study

被引：54

作者：

Calza, L ^{[1
]}

Colangeli, V ^{[1
]}

Manfredi, R ^{[1
]}

Legnani, G ^{[1
]}

Tampellini, L ^{[1
]}

Pocaterra, D ^{[1
]}

Chiodo, F ^{[1
]}

机构：

[1] Univ Bologna, Dept Clin & Expt Med, Infect Dis Sect Alma Mater Studiorum, Bologna, Italy

来源：

AIDS | 2005年 / 19卷 / 10期

关键词：

D O I：

10.1097/01.aids.0000174458.86121.43

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Sixteen HIV-infected patients with protease inhibitor (PI)-related, persisting hypercholesterolaemia were treated with 10 mg a day rostivastatin for 24 weeks. At the end of the observation period, the median reductions in total cholesterol and triglyceride levels versus median baseline values were 21.7 and 30.1%, respectively (P < 0.01). In our small pilot study, rosuvastatin was found to be effective for the treatment of PI-associated hyperlipidaemia, in association with a favourable tolerability profile, without significant clinical or laboratory adverse events.

引用

页码：1103 / 1105

页数：3

共 10 条

[1] Rosuvastatin in the management of hyperlipidemia [J].

Cheng, JWM .

CLINICAL THERAPEUTICS, 2004, 26 (09) :1368-1387

[2]

Cheng-Lai Angela, 2003, Heart Dis, V5, P72, DOI 10.1097/01.HDX.0000050417.89309.F8

[3] Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy:: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group [J].

Dubé, MP ;

Stein, JH ;

Aberg, JA ;

Fichtenbaum, CJ ;

Gerber, JG ;

Tashima, KT ;

Henry, WK ;

Currier, JS ;

Sprecher, D ;

Glesby, MJ .

CLINICAL INFECTIOUS DISEASES, 2003, 37 (05) :613-627

[4]

*FDA, 2004, 21336 NDA

[5] Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial [J].

Hirsch, M ;

O'Donnel, JC ;

Jones, P .

EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2005, 12 (01) :18-28

[6] Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers [J].

Martin, PD ;

Warwick, MJ ;

Dane, AL ;

Hill, SJ ;

Giles, PB ;

Phillips, PJ ;

Lenz, E .

CLINICAL THERAPEUTICS, 2003, 25 (11) :2822-2835

[7] Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection [J].

Penzak, SR ;

Chuck, SK ;

Stajich, GV .

PHARMACOTHERAPY, 2000, 20 (09) :1066-1071

[8] Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: A DISCOVERY study [J].

Strandberg, TE ;

Feely, J ;

Sigurdsson, EL .

CLINICAL THERAPEUTICS, 2004, 26 (11) :1821-1833

[9] Rosuvastatin-induced arrest in progression of renal disease [J].

Vidt, DG ;

Cressman, MD ;

Harris, S ;

Pears, JS ;

Hutchinson, HG .

CARDIOLOGY, 2004, 102 (01) :52-60

[10] Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors [J].

Williams, D ;

Feely, J .

CLINICAL PHARMACOKINETICS, 2002, 41 (05) :343-370

← 1 →